Skip to content

2022 MIPS Measure # TBD: Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer



Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging.

Initial Population

All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer and a qualified encounter in the measurement period.


Equals Initial population

Denominator Exclusions

  • Immunosuppressed patients, includes HIV and immunocompromised state.
  • Immunosuppressive drug therapy.
  • Active Tuberculosis.
  • Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease.
  • Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging.


  • Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series.
  • BCG is initiated within 6 months of the bladder cancer staging and during the measurement period.

Numerator Exclusions

Not Applicable

Denominator Exceptions

Unavailability of BCG

Stay updated with the latest news regarding MACRA and MIPS

The Healthmonix Advisor is a free news source that connects you to the latest in the value-based care industry!

Ready to report like a pro?

See how